Fosfructose

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Fosfructose is a phosphorylated form of fructose indicated in the treatment of hypophosphatemia.

Generic Name
Fosfructose
DrugBank Accession Number
DB13863
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 340.1157
Monoisotopic: 339.996048936
Chemical Formula
C6H14O12P2
Synonyms
  • 1,6-di-O-phosphono-D-fructose
  • D-fructose 1,6-bisphosphate
  • Fosfructose
  • Fructose 1,6-bisphosphate
  • Fructose 1,6-diphosphate
  • Fructose-1,6-diphosphate
  • Harden-young ester
  • keto-D-fructose 1,6-bisphosphate

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofHypophosphatemia•••••••••••••••••••••• ••••••• ••• ••••••••• ••••••• ••• ••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololAcebutolol may increase the arrhythmogenic activities of Fosfructose.
AcetyldigitoxinAcetyldigitoxin may increase the arrhythmogenic activities of Fosfructose.
AdenosineAdenosine may increase the arrhythmogenic activities of Fosfructose.
AjmalineAjmaline may increase the arrhythmogenic activities of Fosfructose.
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Fosfructose.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Fosfructose trisodium463VBZ2YVD81028-91-3BUMXRRGJJDMPRT-PESUWTOCSA-K

Categories

ATC Codes
C01EB07 — Fructose 1,6-diphosphate
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as hexose phosphates. These are carbohydrate derivatives containing a hexose substituted by one or more phosphate groups.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Hexose phosphates
Alternative Parents
Monosaccharide phosphates / Glycerone phosphates / Monoalkyl phosphates / Beta-hydroxy ketones / Acyloins / Alpha-hydroxy ketones / Secondary alcohols / Polyols / Organic oxides / Hydrocarbon derivatives
Substituents
Acyloin / Alcohol / Aliphatic acyclic compound / Alkyl phosphate / Alpha-hydroxy ketone / Beta-hydroxy ketone / Carbonyl group / Glycerone phosphate / Hexose phosphate / Hydrocarbon derivative
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
D-fructose 1,6-bisphosphate (CHEBI:16905)
Affected organisms
Not Available

Chemical Identifiers

UNII
M7522JYX1H
CAS number
488-69-7
InChI Key
XPYBSIWDXQFNMH-UYFOZJQFSA-N
InChI
InChI=1S/C6H14O12P2/c7-3(1-17-19(11,12)13)5(9)6(10)4(8)2-18-20(14,15)16/h3,5-7,9-10H,1-2H2,(H2,11,12,13)(H2,14,15,16)/t3-,5-,6-/m1/s1
IUPAC Name
{[(3S,4R,5R)-3,4,5-trihydroxy-2-oxo-6-(phosphonooxy)hexyl]oxy}phosphonic acid
SMILES
[H][C@@](O)(COP(O)(O)=O)[C@@]([H])(O)[C@]([H])(O)C(=O)COP(O)(O)=O

References

General References
  1. AIFA Product Information: FDP FISIOPHARMA (fosfructose) injection [Link]
ChemSpider
76632
RxNav
2119172
ChEBI
16905
ChEMBL
CHEMBL1235112
ZINC
ZINC000004523259
PDBe Ligand
P6F
PDB Entries
3gb6 / 3t2d / 5f2g / 5f4s / 5tkl / 5tkn / 5tkp / 5ucp / 5ud3

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Powder, for solutionIntravenous10 G
Powder, for solutionIntravenous5 G
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility13.6 mg/mLALOGPS
logP-1.6ALOGPS
logP-3.5Chemaxon
logS-1.4ALOGPS
pKa (Strongest Acidic)1.01Chemaxon
pKa (Strongest Basic)-3.5Chemaxon
Physiological Charge-4Chemaxon
Hydrogen Acceptor Count10Chemaxon
Hydrogen Donor Count7Chemaxon
Polar Surface Area211.28 Å2Chemaxon
Rotatable Bond Count9Chemaxon
Refractivity59.31 m3·mol-1Chemaxon
Polarizability25.52 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0002-8922000000-e52833b8a5a291a52187
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-00kb-0955000000-424463ed06df92a04093
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-00kk-1954000000-c578c6dc8f011032d008
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-000i-0109000000-5374d73d3b6f0d1d67cc
MS/MS Spectrum - , negativeLC-MS/MSsplash10-0002-9100000000-90d958ebad119c7c60f4
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00gl-0197000000-2c666d207be881c4ef28
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0kk9-0392000000-2e114e2ff3476fa48de6
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-056r-1960000000-d78713458d852ddd22e7
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-052b-5900000000-d65f29d5f722e387b3eb
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0002-9000000000-3b992f02b655d8e877c3
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-0059000000-62a4353195165b764e69
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-1009000000-7a0f14fde92f32d36a48
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-3920000000-c0807f20c10623c9ed34
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-004j-9000000000-b9f905f6440dcad54c99
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-9000000000-bcba9085f798d390d292
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0005-8910000000-b49dc630fe325a0daa3f
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-169.2052665
predicted
DarkChem Lite v0.1.0
[M-H]-157.13152
predicted
DeepCCS 1.0 (2019)
[M+H]+173.3752665
predicted
DarkChem Lite v0.1.0
[M+H]+159.52745
predicted
DeepCCS 1.0 (2019)
[M+Na]+169.0672665
predicted
DarkChem Lite v0.1.0
[M+Na]+165.80098
predicted
DeepCCS 1.0 (2019)

Drug created at June 26, 2017 20:23 / Updated at May 21, 2021 10:23